Abstract

Amgen will report its latest quarterly results on August 4, 2026 Post Market, with investor attention centered on revenue momentum, earnings quality, and regulatory developments around select therapies that could shape second-half performance and sentiment.

Market Forecast

Consensus anticipates Amgen to deliver revenue of 9.42 billion US dollars this quarter, up 5.44% year over year, with adjusted EPS of 5.62, up 6.20% year over year; EBIT is projected at 4.18 billion US dollars, implying 4.60% year-over-year growth. Margin forecasts are not broadly quantified in market previews, keeping the focus on top-line cadence and earnings conversion. The main revenue engine remains the company’s products business, where consistency of prescription trends and price/mix should guide quarter-on-quarter execution. The most promising commercial contributor continues to be the products portfolio overall, which generated 8.22 billion US dollars last quarter against a company-level revenue growth rate of 5.76% year over year, setting a baseline for this quarter’s trajectory.

Last Quarter Review

Amgen’s previous quarter delivered revenue of 8.62 billion US dollars, a gross profit margin of 71.03%, GAAP net profit attributable to the parent company of 1.82 billion US dollars, a net profit margin of 21.11%, and adjusted EPS of 5.15, up 5.10% year over year. A notable financial highlight was the quarter-on-quarter rebound in net profit, which rose 36.46% as operating leverage and cost discipline supported earnings flow-through. In terms of business mix, the products segment contributed 8.22 billion US dollars and other income totaled 400.00 million US dollars, with company-level revenue increasing 5.76% year over year.

Current Quarter Outlook

Products portfolio execution and near-term earnings dynamics

Amgen’s near-term performance is anchored by its products portfolio, which accounted for 8.22 billion US dollars last quarter and underpins the quarter’s revenue and EPS trajectory. With consensus pointing to 9.42 billion US dollars in revenue and 5.62 in adjusted EPS this quarter, the debate centers on prescription trends, price/mix, and the durability of high-60s to low-70s gross margin as indicated by the 71.03% result last quarter. Stable utilization patterns and continued commercial execution are likely to keep revenue cadence close to expectations, while operating expense phasing and cost controls will influence EPS conversion. Legal and policy developments may provide incremental support to revenue stability. Amgen obtained a preliminary injunction preventing Colorado from imposing price caps on Enbrel, reducing near-term pricing risk on a key immunology franchise and supporting the visibility of product-level cash flows. That outcome, alongside disciplined cost management, helps de-risk downside scenarios embedded in some conservative models and should modestly improve confidence in this quarter’s EBIT delivery, which the market pegs at 4.18 billion US dollars. Regulatory headlines elsewhere, however, require monitoring. The evolving situation around Tavneos in Europe and the United States introduces uncertainty around an asset that previously displayed rapid growth. While the absolute sales base is smaller than major legacy products, sentiment spillover can influence the stock, particularly if investors extrapolate broader regulatory risk. For this quarter’s P&L, the principal question remains whether core franchises offset pockets of volatility so that total revenue and EPS meet or modestly exceed consensus.

Largest growth potential within the commercial base

Over the last quarter, the core products portfolio remained the most substantial and investable growth platform, contributing 8.22 billion US dollars and benefiting from a 5.76% company-level revenue growth rate year over year. This concentration of revenue and earnings power means even modest outperformance across key therapies can materially improve quarterly results. The breadth of the commercial base also provides a buffer against idiosyncratic events on individual assets, sustaining aggregate growth and earnings predictability. Pipeline-to-commercial transitions add optionality to this growth base. Progress in the oncology portfolio, including ongoing development programs and regional expansions, can translate into incremental revenue as access broadens. While contributions from newer oncology modalities may be limited in the current quarter, continued clinical and regulatory advancement remains a medium-term driver that investors will track for its potential to lift trajectory and diversify earnings. Management’s ability to maintain pricing discipline, protect access, and emphasize high-value indications will be important for sustaining the quarter-on-quarter momentum. Given the strong gross margin profile in the prior quarter and a net margin of 21.11%, even subtle improvements in operating efficiency can enhance EPS for a given level of revenue. The market’s 5.44% year-over-year revenue forecast thus represents a reasonable baseline from which upside could emerge if prescription trends or mix skew positively.

Stock-price drivers this quarter

Delivery versus consensus is the first-order variable. With revenue projected at 9.42 billion US dollars and EBIT at 4.18 billion US dollars, modest beats on either top line or operating income can lift EPS above 5.62, reinforcing the multi-quarter narrative of steady growth and cost control. Conversely, any shortfall in product volumes or an adverse mix shift that compresses gross margin relative to last quarter’s 71.03% could weigh on EPS and reset expectations for the second half. Regulatory and legal updates are the second key driver. The preliminary injunction on Enbrel pricing in Colorado supports the commercial outlook for that franchise and reduces concerns about near-term price ceilings in a large U.S. market. On the other hand, the European regulatory challenges and U.S. scrutiny associated with Tavneos create headline risk. Should there be incremental clarity that stabilizes the future of the product, it would remove an overhang; adverse developments could have a disproportionate impact on sentiment relative to near-term financials, given the asset’s growth profile in the recent past. Pipeline progress and lifecycle innovation round out the quarter’s catalysts. Clinical readouts and label or access expansions, including subcutaneous formulations under evaluation for important therapies, are being watched for evidence of higher patient adoption and payer receptivity. These developments may not shift this quarter’s revenue materially, but they influence valuation by informing medium-term growth scenarios. Investors will also parse any color Amgen provides on capital allocation, including the balance between R&D investment, debt management, and shareholder returns, to gauge the sustainability of EPS growth and the potential for incremental operating leverage.

Analyst Opinions

The majority of recent institutional commentary skews bullish. Among the most recent and specific views collected since January 1, 2026, there are multiple Buy/Overweight stances versus a smaller number of negative ratings, yielding an approximate bullish-to-bearish ratio of 4:1. Notably, Goldman Sachs maintained a Buy rating while nudging its target to 427.00 US dollars, emphasizing confidence in execution and medium-term earnings power. UBS lifted its target to 420.00 US dollars with a Buy rating, citing the breadth of revenue contributors and the potential from emerging assets. Piper Sandler reiterated a Buy rating with a 432.00 US dollars target and highlighted continued revenue momentum and opportunities across the commercial and late-stage portfolio. BMO Capital maintained a Buy rating with a 400.00 US dollars target, pointing to constructive EPS visibility relative to consensus in the upcoming print. RBC offered an explicitly positive view on the diversified business and emerging pipeline, underscoring resilience of near-term revenue alongside optionality from the development slate. Neutral stances form a meaningful minority yet remain outweighed by the positive cohort. Morgan Stanley maintained an Equal Weight view while adjusting its target to 340.00 US dollars, citing limited near-term upside in the absence of larger catalysts but acknowledging the company’s long-term potential. Raymond James and Guggenheim also sit at Hold. On the cautious side, Bank of America retained an Underperform rating with a target at 312.00 US dollars, flagging patent and product-specific risks that could restrain upside. Even factoring in that dissenting position and a more conservative target from a separate institution that remains below consensus, the balance of recent opinion aligns with a favorable short-term setup heading into the report. Why the bullish view dominates becomes clearer when triangulating forecasts and operational signals. Consensus looks for revenue growth of 5.44% year over year and adjusted EPS growth of 6.20% year over year, levels that are achievable if core franchises hold their run-rate and gross margin remains near last quarter’s 71.03%. The preliminary injunction protecting Enbrel pricing in Colorado reduces policy-risk asymmetry, and the market reads this as supportive of revenue durability in a key category. Meanwhile, pipeline and lifecycle initiatives—such as progress toward subcutaneous delivery in select oncology assets—strengthen the medium-term growth story, even if the near-term P&L impact is modest. Analysts also emphasize earnings quality. With the prior quarter’s net margin at 21.11% and EBIT delivery above internal forecasts, a repeat of disciplined operating expense control could produce an EPS beat without requiring significant upside on the top line. The previous quarter’s adjusted EPS of 5.15 grew 5.10% year over year, and the quarter-on-quarter rebound in GAAP net profit of 36.46% demonstrates sensitivity of bottom-line results to incremental revenue and cost leverage. This dynamic underpins the constructive case that even in the face of discrete regulatory headlines, the company can meet or slightly exceed consensus on August 4, 2026 Post Market and maintain full-year momentum. A final thread running through supportive research is the view that recent legal and regulatory developments have been more mixed than negative when considered in aggregate. On one hand, the Colorado injunction meaningfully reduces a near-term pricing risk for a major product. On the other, European actions regarding Tavneos and ongoing U.S. dialogue around that therapy introduce uncertainty that investors will want management to address. The net of these crosscurrents, in the eyes of the bullish camp, still favors delivery of in-line to better-than-expected second-quarter results. If management can provide clarity that narrows perceived downside tails while reaffirming cost discipline and commercial execution, bullish analysts argue that the shares can sustain a premium to cautious targets that assume heavier policy and regulatory drag. In sum, the prevailing institutional stance entering the print is positive, anchored by confidence in the products portfolio’s consistency, cost discipline that supports EPS delivery, and a pipeline that continues to mature. The minority cautious view highlights known regulatory issues and product-specific risks, but recent price-target increases and reiterated Buy ratings suggest that, for most covering institutions, the expected 5.44% revenue growth and 6.20% EPS growth set a reasonable bar that the company can meet or modestly surpass this quarter.